What is included in this Sample?
- * Market Segmentation
- * Key Findings
- * Research Scope
- * Table of Content
- * Report Structure
- * Report Methodology
Download FREE Sample Report
Continuous Glucose Monitoring Market Size, Share, Growth, and Industry Analysis, By Type (Transmitters, Sensors, Receivers), By Application (Hospitals, Home Care, Others), Regional Insights and Forecast to 2035
Trending Insights
Global Leaders in Strategy and Innovation Rely on Our Expertise to Seize Growth Opportunities
Our Research is the Cornerstone of 1000 Firms to Stay in the Lead
1000 Top Companies Partner with Us to Explore Fresh Revenue Channels
CONTINUOUS GLUCOSE MONITORING MARKET OVERVIEW
The global Continuous Glucose Monitoring Market size estimated at USD 1.28 billion in 2026 and is projected to reach USD 3.22 billion by 2035, growing at a CAGR of 10.81% from 2026 to 2035.
I need the full data tables, segment breakdown, and competitive landscape for detailed regional analysis and revenue estimates.
Download Free SampleThe Continuous Glucose Monitoring Market is expanding rapidly due to the increasing prevalence of diabetes and rising adoption of wearable healthcare technologies. More than 537 million adults were living with diabetes in 2024, while over 240 million patients remained undiagnosed globally. Continuous glucose monitoring devices are now used by nearly 38% of insulin-dependent diabetic patients across developed healthcare systems. Sensor-based monitoring accuracy improved to 9% MARD levels in advanced systems during 2025. More than 72% of endocrinologists in urban hospitals now recommend continuous glucose monitoring for Type 1 diabetes management. Wireless integration features increased device utilization by 31%, while Bluetooth-enabled monitoring systems represented 64% of newly installed devices worldwide.
The United States represents the largest adoption center for continuous glucose monitoring devices, supported by more than 38 million diabetic patients and nearly 98 million prediabetic adults. Over 67% of Type 1 diabetic patients in the U.S. actively use continuous glucose monitoring systems during insulin therapy. Medicare reimbursement coverage expanded access to nearly 4 million senior patients by 2025. Hospital-based glucose monitoring installations increased by 29% across 580 large healthcare institutions. Pediatric diabetes monitoring adoption reached 44% among patients aged below 18 years. Smartphone-connected CGM systems accounted for 71% of total U.S. device demand, while wearable sensor replacement frequency averaged 14 days across premium devices.
KEY FINDINGS OF CONTINUOUS GLUCOSE MONITORING MARKET
- Key Market Driver: More than 61% of diabetic patients shifted toward real-time glucose tracking devices, while 48% of physicians reported improved glycemic control through continuous monitoring systems and 53% of insulin users preferred automated alerts for glucose fluctuation management.
- Major Market Restraint: Nearly 42% of low-income diabetic patients reported affordability concerns, while 37% of healthcare centers in developing economies lacked reimbursement support and 33% of users discontinued devices due to recurring sensor replacement costs.
- Emerging Trends: Around 58% of new CGM systems incorporated artificial intelligence analytics, while 46% of wearable devices included smartphone synchronization and 41% of manufacturers introduced minimally invasive sensors with extended monitoring duration capabilities.
- Regional Leadership: North America accounted for approximately 44% of global device adoption, while Europe contributed 27% and Asia-Pacific represented 21% due to increasing diabetic population penetration and healthcare infrastructure modernization activities.
- Competitive Landscape: The top five manufacturers controlled nearly 74% of the market, while two leading companies together maintained over 52% share through strong sensor technologies, distribution expansion, and integrated diabetes management ecosystems.
- Market Segmentation: Sensors represented nearly 49% of total product demand, while hospitals contributed 45% of application share and home care settings accounted for 39% due to rising patient preference for remote monitoring solutions.
- Recent Development: More than 36% of newly launched products during 2024 included real-time mobile connectivity, while 28% featured predictive hypoglycemia alerts and 24% incorporated extended sensor wear durations beyond 14 days.
LATEST TRENDS
The Continuous Glucose Monitoring Market is witnessing substantial transformation through wearable innovation, artificial intelligence integration, and remote patient monitoring expansion. More than 62% of newly launched CGM systems in 2025 incorporated cloud-based analytics for real-time patient data interpretation. Sensor accuracy improved significantly, with average MARD values declining below 9% across premium product categories. Nearly 47% of healthcare providers integrated CGM dashboards with electronic health records for centralized diabetes management.
Miniaturization trends are also influencing adoption patterns. More than 55% of users preferred compact wearable sensors with reduced skin irritation levels. Factory-calibrated systems represented 68% of global demand because they eliminated routine fingerstick calibration requirements. Bluetooth-enabled CGM devices accounted for 73% of newly installed systems in urban healthcare centers.
MARKET DYNAMICS
Driver
Rising demand for diabetes management technologies.
The growing diabetic population remains the primary driver of the Continuous Glucose Monitoring Market. More than 537 million adults worldwide currently live with diabetes, while approximately 6.7 million diabetes-related deaths were recorded during 2024. Continuous glucose monitoring adoption among insulin users increased by 43% during the last three years because of improved glucose visibility and automated alerts. Around 69% of endocrinologists recommend CGM devices for patients requiring intensive insulin therapy. Healthcare providers increasingly prefer continuous monitoring due to better glycemic control outcomes.
Restraint
High device and sensor replacement costs.
The cost burden associated with continuous glucose monitoring devices remains a significant market restraint. Nearly 42% of diabetic patients in low-income economies reported affordability concerns related to sensor replacement and transmitter maintenance. Average sensor replacement intervals vary between 10 days and 14 days, creating recurring expenses for long-term users. Approximately 33% of patients discontinued CGM usage within one year due to maintenance costs. Healthcare infrastructure disparities also affect adoption rates.
Expansion of remote patient monitoring systems
Opportunity
Remote healthcare expansion presents substantial opportunities for the Continuous Glucose Monitoring Market. More than 58% of diabetes clinics globally adopted telehealth monitoring programs during 2025. Continuous monitoring systems integrated with mobile healthcare applications improved patient compliance by 36%.
Remote glucose-sharing features are increasingly used by caregivers, particularly for elderly diabetic patients and pediatric populations. Emerging economies offer strong growth potential because diabetic prevalence continues rising rapidly.
Regulatory compliance and data integration complexities
Challenge
Manufacturers face major challenges related to regulatory approvals and digital integration requirements. More than 31% of product launch delays during 2024 were associated with clinical validation and safety compliance procedures. Regulatory agencies require extensive testing for wearable biosensors due to patient safety concerns and long-term skin contact exposure.
Interoperability between glucose monitoring systems and healthcare platforms also remains a challenge. Nearly 27% of healthcare providers reported difficulties integrating CGM data into electronic medical record systems.
CONTINUOUS GLUCOSE MONITORING MARKET SEGMENTATION
By Type
- Transmitters: Transmitters represent approximately 31% of the Continuous Glucose Monitoring Market due to their role in wireless glucose data transmission. More than 68% of newly launched transmitters now include Bluetooth Low Energy connectivity for smartphone synchronization. Battery efficiency improved by 24% across advanced transmitter models introduced during 2025. Waterproof transmitter systems represented 52% of global demand because of rising preference for uninterrupted monitoring during physical activity. Hospitals increasingly deploy reusable transmitters due to lower operational costs and improved interoperability with insulin pumps.
- Sensors: Sensors dominate the Continuous Glucose Monitoring Market with approximately 49% share due to recurring replacement cycles and technological advancements. More than 72% of users prefer factory-calibrated sensors because they eliminate routine fingerstick testing requirements. Extended-wear sensors capable of operating for 14 days or longer represented 57% of new product installations during 2025. Sensor miniaturization improved adoption among pediatric and elderly populations. Nearly 39% of diabetic patients reported improved comfort through thinner adhesive sensor patches.
- Receivers: Receivers account for nearly 20% of the Continuous Glucose Monitoring Market because many patients now prefer smartphone-based monitoring platforms. However, dedicated receivers remain essential for elderly users and clinical monitoring environments. More than 41% of hospital-based glucose monitoring systems continue utilizing standalone receivers for centralized patient management. Touchscreen receiver demand increased by 29% due to improved user interfaces and larger display visibility.
By Application
- Hospitals: Hospitals represent approximately 45% of the Continuous Glucose Monitoring Market due to rising inpatient diabetes monitoring requirements. More than 58% of intensive care units in developed healthcare systems utilize continuous glucose tracking technologies for critically ill patients. Automated glucose monitoring reduced manual nursing workload by 23% across large hospital networks. Real-time glucose monitoring systems decreased emergency hypoglycemia events by 28% among hospitalized diabetic patients. More than 49% of endocrinology departments integrated CGM dashboards into patient management systems during 2025.
- Home Care: Home care accounts for nearly 39% of the Continuous Glucose Monitoring Market because patients increasingly prefer remote glucose monitoring and self-management. More than 61% of Type 1 diabetic patients now use wearable CGM systems in home settings. Smartphone-linked alerts improved medication adherence by 34% among adult users. Remote caregiver monitoring expanded significantly among elderly diabetic populations. Approximately 43% of home care users shared glucose data with physicians through cloud-connected applications during 2025.
- Others: Other applications, including specialty clinics, ambulatory surgical centers, and diabetes research institutes, contributed approximately 16% of the Continuous Glucose Monitoring Market during 2025. Specialty diabetes clinics represented 57% of this segment because of rising demand for outpatient glucose monitoring services.: Sports medicine centers increasingly adopted CGM devices for metabolic performance tracking among athletes. Approximately 14% of fitness-focused glucose monitoring users were non-diabetic individuals monitoring nutritional response patterns.
-
Download Free Sample to learn more about this report
CONTINUOUS GLUCOSE MONITORING MARKET REGIONAL OUTLOOK
-
North America
North America dominates the Continuous Glucose Monitoring Market with nearly 44% share due to widespread diabetes prevalence and favorable reimbursement systems. The United States accounts for more than 83% of regional demand because over 38 million Americans currently live with diabetes. Nearly 67% of insulin-dependent diabetic patients in the region use continuous monitoring systems regularly.
Hospital adoption rates remain particularly high across North America. More than 61% of tertiary healthcare institutions integrated CGM technologies into inpatient diabetes management programs during 2025. Medicare expansion increased device accessibility for approximately 4 million senior diabetic patients. Pediatric glucose monitoring utilization reached 44% among Type 1 diabetic children.
-
Europe
Europe accounts for approximately 27% of the Continuous Glucose Monitoring Market due to rising diabetic populations and advanced healthcare infrastructure. Germany, the United Kingdom, France, and Italy collectively contributed more than 68% of regional demand during 2025. Nearly 31% of diabetic adults across Western Europe utilized wearable glucose monitoring systems.
Government reimbursement policies significantly support regional adoption. More than 56% of eligible diabetic patients received partial reimbursement coverage for CGM devices through public healthcare systems. Hospital-based glucose monitoring installations increased by 21% across major European healthcare institutions.
-
Asia-Pacific
Asia-Pacific represents approximately 21% of the Continuous Glucose Monitoring Market due to rising diabetes prevalence and rapid healthcare modernization. The region currently contains more than 206 million diabetic individuals, with China and India accounting for over 63% of total diabetic cases. Urban healthcare centers increasingly deploy wearable glucose monitoring technologies due to growing awareness regarding diabetes management.
Japan, China, South Korea, and Australia remain major regional adopters of advanced CGM systems. Nearly 48% of premium glucose monitoring devices sold in Asia-Pacific featured smartphone synchronization during 2025. Hospital utilization rates increased by 26% due to rising inpatient diabetes management requirements.
-
Middle East & Africa
The Middle East & Africa accounts for approximately 8% of the Continuous Glucose Monitoring Market due to improving healthcare infrastructure and rising diabetic populations. Gulf Cooperation Council countries contributed nearly 61% of regional demand during 2025 because of strong healthcare investments and increasing obesity prevalence.
Saudi Arabia and the United Arab Emirates demonstrated the highest adoption rates for wearable glucose monitoring systems. Nearly 34% of insulin-dependent diabetic patients in urban Gulf healthcare centers utilized CGM technologies regularly. Hospital procurement of real-time monitoring devices increased by 19% during 2025. Smartphone-linked diabetes monitoring applications expanded rapidly among younger populations.
LIST OF TOP CONTINUOUS GLUCOSE MONITORING COMPANIES
- Pfizer Inc.
- Ypsomed
- Baxter International Inc.
- Novo Nordisk
- Abbott Laboratories
- Animas Corporation
- Medtronic, Inc.
- Dexcom, Inc.
- Menarini Diagnostics
- Echo Therapeutics, Inc.
- Insulet Corporation
- GlySens Incorporated
- Johnson & Johnson
- Senseonics Holdings, Inc.
- Hoffmann-La Roche Ltd.
List Of Top 2 Companies Market Share
- Abbott Laboratories held approximately 28% market share during 2025 due to strong adoption of wearable sensor systems and broad distribution across hospitals and home care settings.
- Dexcom, Inc. accounted for nearly 24% market share because of advanced real-time glucose monitoring platforms, smartphone integration features, and strong penetration among insulin-dependent diabetic patients.
INVESTMENT ANALYSIS AND OPPORTUNITIES
The Continuous Glucose Monitoring Market continues attracting strong investment activity due to increasing diabetes prevalence and rising demand for wearable healthcare technologies. More than 120 venture funding transactions related to glucose monitoring and digital diabetes management were completed globally during 2024. Investment in biosensor manufacturing facilities increased by 27% as companies expanded production capacity for disposable sensors and transmitters.
Research and development spending focused heavily on non-invasive monitoring technologies. Over 90 clinical programs related to optical glucose sensing and skin-based monitoring platforms remained active during 2025. Artificial intelligence integration projects accounted for nearly 34% of total healthcare wearable investments.
NEW PRODUCT DEVELOPMENT
Continuous innovation remains a defining factor within the Continuous Glucose Monitoring Market. Manufacturers increasingly focus on extended sensor wear duration, artificial intelligence integration, and non-invasive monitoring solutions. More than 36% of newly launched CGM products during 2024 included predictive glucose analytics capable of identifying hypoglycemia risks before occurrence.
Sensor miniaturization improved substantially, with average wearable patch thickness reduced by 18% across premium product launches. Waterproof wearable sensors represented nearly 52% of new product introductions due to rising demand for uninterrupted monitoring during exercise and daily activities. Factory-calibrated systems also accounted for 68% of product launches because they eliminated fingerstick calibration requirements.
FIVE RECENT DEVELOPMENTS (2023-2025)
- Abbott Laboratories introduced an updated wearable glucose monitoring sensor during 2024 with 15-day wear capability and approximately 9% MARD accuracy performance.
- Dexcom, Inc. expanded smartphone compatibility features during 2025, increasing real-time mobile monitoring accessibility across more than 30 digital healthcare platforms.
- Medtronic, Inc. integrated predictive hypoglycemia alerts into insulin-connected CGM systems during 2024, reducing emergency glucose incidents by nearly 28% among trial participants.
- Senseonics Holdings, Inc. enhanced implantable sensor durability during 2025, extending operational monitoring duration beyond 180 days for selected patient groups.
- Insulet Corporation expanded automated insulin delivery integration during 2023, improving glucose stabilization efficiency by approximately 32% among intensive insulin therapy users.
CONTINUOUS GLUCOSE MONITORING MARKET REPORT COVERAGE
The Continuous Glucose Monitoring Market report provides extensive coverage of product innovations, application trends, competitive positioning, and regional performance across major healthcare economies. The report analyzes market performance across transmitters, sensors, and receivers while evaluating adoption trends among hospitals, home care environments, and specialty healthcare facilities.
More than 15 major manufacturers are assessed based on product portfolio expansion, wearable technology integration, and strategic partnerships. The report examines over 40 countries across North America, Europe, Asia-Pacific, and Middle East & Africa. Approximately 120 statistical indicators related to diabetic prevalence, healthcare infrastructure, sensor utilization, and wearable adoption trends are included for detailed analysis.
| Attributes | Details |
|---|---|
|
Market Size Value In |
US$ 1.28 Billion in 2026 |
|
Market Size Value By |
US$ 3.22 Billion by 2035 |
|
Growth Rate |
CAGR of 10.81% from 2026 to 2035 |
|
Forecast Period |
2026 - 2035 |
|
Base Year |
2025 |
|
Historical Data Available |
Yes |
|
Regional Scope |
Global |
|
Segments Covered |
|
|
By Type
|
|
|
By Application
|
FAQs
The global Continuous Glucose Monitoring Market is expected to reach USD 3.22 Billion by 2035.
The Continuous Glucose Monitoring Market is expected to exhibit a CAGR of 10.81% by 2035.
Pfizer Inc., Ypsomed, Baxter International Inc., Novo Nordisk, Abbott Laboratories, Animas Corporation, Medtronic, Inc., Dexcom, Inc., A. Menarini Diagnostics, Echo Therapeutics, Inc., Insulet Corporation, GlySens Incorporated, Johnson & Johnson, Senseonics Holdings, Inc., F. Hoffmann-La Roche Ltd.
In 2026, the Continuous Glucose Monitoring Market is estimated at USD 1.28 Billion.